Healthcare / Diagnostics & ResearchStockholm
$0.44
-0.02 (-3.70%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 17%
FCF escenarios
weak_data · normalized FCF $-37.7M · quality 41.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
0/100
F
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$26M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-167.7%
↓Gross Margin
100.0%
↑Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-4.5%
FCF CAGR
—
FCF margin
-6269.5%
FCF / Net income
0.84x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $594000.0 · net income $-44.5M · FCF $-37.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $594000.00 | $594000.00 | $199000.00 | $1.4M | $683000.00 |
| Net Income | $-44.5M | $-44.5M | $-41.1M | $-41.4M | $-29.1M |
| EBITDA | $-40.7M | $-40.7M | $-37.4M | $-38.0M | $-26.8M |
| EPS | -1.32 | -1.32 | -14.93 | -187.95 | -323.24 |
| Gross Margin | 100.0% | 100.0% | 963.8% | 274.9% | 100.0% |
| Operating Margin | -6555.2% | -6555.2% | -20529.6% | -2894.3% | -4200.4% |
| Net Margin | -7492.1% | -7492.1% | -20628.6% | -3055.7% | -4258.7% |
| Balance Sheet | |||||
| Debt/Equity | — | — | 0.00 | 0.47 | 0.03 |
| Current Ratio | 0.44 | 0.44 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-37.2M | $-37.2M | $-52.6M | $-37.7M | $-27.7M |
| Returns | |||||
| ROE | -167.7% | -167.7% | -122.7% | -167.9% | -111.2% |
| Valuation | |||||
| P/B | 0.56 | 0.56 | 451.01 | 215.21 | 0.54 |
| Growth & Yield | |||||
| Revenue Growth | 198.5% | 198.5% | -85.3% | 98.5% | — |
| EPS Growth | 91.2% | 91.2% | 92.1% | 41.9% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-64.7%
Start / end P/E
n/dx → n/dx
EPS bridge
-14.93 → -1.32
Residual
-64.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.